1. Home
  2. CRAI vs AVLN Comparison

CRAI vs AVLN Comparison

Compare CRAI & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRA International Inc.

CRAI

CRA International Inc.

SELL

Current Price

$177.01

Market Cap

1.2B

ML Signal

SELL

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

BUY

Current Price

$24.54

Market Cap

1.3B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CRAI
AVLN
Founded
1965
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
1998
2026

Fundamental Metrics

Financial Performance
Metric
CRAI
AVLN
Price
$177.01
$24.54
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
★ $250.50
$61.80
AVG Volume (30 Days)
88.9K
★ 294.6K
Earning Date
10-29-2026
11-25-2026
Dividend Yield
★ 1.30%
N/A
EPS Growth
★ 20.77
N/A
EPS
★ 8.14
N/A
Revenue
★ $751,583,000.00
N/A
Revenue This Year
$8.35
N/A
Revenue Next Year
$4.01
N/A
P/E Ratio
$21.57
★ N/A
Revenue Growth
★ 9.33
N/A
52 Week Low
$132.17
$22.68
52 Week High
$227.29
$40.17

Technical Indicators

Market Signals
Indicator
CRAI
AVLN
Relative Strength Index (RSI) 61.44 32.78
Support Level $153.02 N/A
Resistance Level $194.00 $30.45
Average True Range (ATR) 5.27 1.60
MACD 1.14 -0.17
Stochastic Oscillator 84.14 31.17

Price Performance

Historical Comparison
CRAI
AVLN

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: